ArticleACS pharmacology & translational science2020

Empagliflozin and Doxorubicin Synergistically Inhibit the Survival of Triple-Negative Breast Cancer Cells via Interfering with the mTOR Pathway and Inhibition of Calmodulin:

Shenouda G Eliaa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.